Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France -1- We gratefully acknowledge the support of our sponsors CONTENTS WELCOME .................................................................. 4 CONGRESS INFORMATION ...................................... 5 GENERAL INFORMATION .......................................... 6 AGENDA ...................................................................... 8 ............................................. 8 SATURDAY, OCTOBER 3 -2- ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France SUNDAY, OCTOBER 4 ............................................... 10 MONDAY, OCTOBER 5 .............................................. 11 TUESDAY, OCTOBER 6 ............................................. 12 SPEAKER BIOGRAPHIES ......................................... 14 NOTEPAD .................................................................. 23 ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France -3- WELCOME On behalf of the Organizing Committee we are delighted to welcome you to Corsica for the ICAV/ CITAV 8th International Symposium. The symposium will assemble leading scientists, public health experts, industry representatives, and philanthropic organizations to advance the development of safe, affordable and effective anti-viral therapeutics for infectious diseases. CONGRESS INFORMATION Key Objectives Key objectives of the symposium are: Identify novel therapeutic avenues in the HIV field Integrate all aspects related to Dengue research in order to organise and impact the nascent field of emerging virus control strategies Identify and bridge the gaps in the rapidly evolving field of emerging viruses Focus on the global public health response to H1N1 Identify and develop innovating funding and spending mechanisms where public attention is competing with the worldwide financial crisis. Meals and accommodations incurred in connection with attending the Symposium will be covered for approved registrants. Unfortunately we are unable to cover travel costs to and from this meeting. Accommodation will be at the Hotel Coralia Club Porticcio Marina Viva. The symposium will take place at the Palais des Congrès et des Expositions d’Ajaccio in Ajaccio, Corsica. Transfers Transfers from Hotel to Convention Centre and back by boat, please check the practical information memo sent out before the congress for departure times. Posters Poster set-up will take place Saturday afternoon. Official time for viewing is scheduled Sunday October 4 afternoon. Please ensure that you remove your poster before 4 pm on Monday October 5. Organizing Committee Bruno Canard Jeremy Carver Lorin Charlton Michel Chrétien Rolf Hilgenfeld Christine Hodge Rajan Shah Contact Contact Agency ATouT.Com Aix en Provence - France www.atoutcom.com Cell phone contact: Anette +33 (0)6 27 40 39 77 Elysabeth +33 (0)6 68 69 85 40 -4- ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France -5- GENERAL INFORMATION Ferry Information ICAV will cover the ferry cost from Marseille to Ajaccio and back. Name of boat: Napoléon Bonaparte 2nd October Marseille - Ajaccio (Corsica): Departure: 8 pm (the group needs to be there 1h30 in advance) Arrival 7 am on October 3rd 6th October Ajaccio - Marseille: Location Ajaccio where the Convention Centre (« Palais de Congrès » in French) is located, lies on the West coast of the island of Corsica in a sheltered position at the foot of wooded hills on the Northern shore of the Gulf of Ajaccio. The harbour lies to the east of the town and is protected in the South by a peninsula. Napoleon Bonaparte was borne there in 1769. His memory is firmly entrenched in the city and is further embellished by the many gifts his family, descendants and admirers donated to the city. The Conference Hotel, Coralia Club Marina Viva, is located in the heart of the seaside resort of Porticcio, 17 km from the Convention Centre. This hotel by the sea amidst trees and flower-filled gardens looks out on the Gulf of Ajaccio and the Sanguinaire Islands. Departure : 8 pm (the group needs to be there 1h30 in advance) Arrival 7.30 am on October 7th Details: Accommodation in outside single (double for participants with guest) cabins (with window) with bathroom. Welcome cocktail on upper level of Bar « Le Galaxie » (deck 11). Dinner and breakfast in private dining room « Le Sillage d’Argent » (deck 9). Pratical Information Currency: 1 Euro = 100 centimes (= 1,58 CAD on 09/29/09) Telephone: The international code is 00 + country code The international access code for France is +33 Electricity: Electrical current is 220 volts, 50 Hz. European two-pin plugs are standard. Don’t forget your adaptors and converters. ATM machines: There is no ATM teller inside the Hotel Club, but there are banks with ATM tellers nearby (Crédit Agricole) -6- ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France -7- AGENDA October 3-6, 2009 Leave on overnight ferry from Marseille to Ajaccio on the evening of Oct 2nd. On board you are invited to attend the welcome cocktail reception on the upstairs level of the bar “Le Galaxie” at 7.30 pm. The reception is being sponsored by Arrow Therapeutics/Astra Zeneca. Dinner will follow at 8:30 pm. We will arrive in Corsica at ~ 7 am Oct 3rd. Session 2: HIV - Present and Future Challenges Focus: What’s next in the HIV field regarding novel therapeutic avenues, vaccine design, community-based awareness, and innovative funding and incentives in a global context where public attention is competed by the worldwide financial crisis as well as novel pandemic threats? Chair: Bruno Canard 1:00-1:45 pm Anne-Sophie Beignon (Pasteur Institute, France) “AIDS vaccine: where are we now?” All sessions in Ajaccio Oct 3-6 1:45-2:30 pm Jan ter Meulen (Merck, USA) The format will be several presentations on each topic followed by a panel. Each panelist will be asked to make a brief presentation; the panel will then be opened for questions from the floor. 2:30-3:00 pm Jörg Hofmann (Charité Campus Benjamin Franklin, Germany) 3:00-3:30 pm COFFEE BREAK 3:30-4:00 pm Evelyne Jacqz-Aigrain (hospital Robert Debre, France) 4:00-4:30 pm R.S. Paranjape (NARI, India) 4:30-5:00 pm Bruno Spire (INSERM, France) 5:00-5:30 pm Panelists: Saturday, October 3 Session 1: Go viral: Innovative financing - Innovative spending Focus: The UNITAID funding model is evolving. This innovative funding model will be presented by Dr. Philippe Douste-Blazy, UN Under-Secretary for Innovative Financing. The research and drug & diagnostic development communities need to develop an « innovative spending » model that meets the expectations of these emerging innovative funding mechanisms. ICAV will present a « straw-man » proposal for discussion and elaboration. Chair: Michel Chrétien (OHRI, Canada) 10:00-10:45 am Philippe Douste-Blazy (UNITAID, France) 10:45-11:30 am Jeremy Carver (ICAV, Canada) « Suggestions for Innovative Spending » 12:00-1:00 pm LUNCH -8- ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France « Long-term control of HIV by allogeneic CCR5-U32/U32 stem cell transplantation » « How to increase availability of drugs for children : scientific and regulatory aspects » « Virology of Indian HIV epidemic and initiatives for anti-HIV drug development » « Perceptions and behaviors of people living with HIV/AIDS : the interest of a multidisciplinary approach » Anna Vyakarnam (King’s College, UK) James Brandful (Noguchi Memorial Inst. of Medical Research, Ghana) Jonathan Stoye (Mill Hill, UK) Dana Wolf (Hadassah University Hospital, Israel) 11:30-12:00 pm Panelists & Discussion: R.S. Paranjape (NARI, India) Oyekanmi Nashiru (ICAV, Nigeria) Sunday Omilabu (University of Lagos, Lagos) « Current challenges to the development of HIV vaccines and antivirals » 5:30-6:00 pm Discussion 7:00-9:00 pm COCKTAILS AND DINNER ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France -9- Sunday, October 4 Monday, October 5 Session 3: Dengue - An integrated model Sessions 4 & 5: Emerging Viruses for arthropod-borne viral disease control Focus: Dengue is a robustly emerging disease transmitted by mosquitoes of the Aedes species in tropical and subtropical areas of the world. The global disease burden and control challenge has made of Dengue a model for other arthropod-borne diseases in terms of science, prevention, vector control, community-based measures, societal and economic impact. The goal of this session is to integrate all aspects related to dengue research in order to organize and impact the nascent field of emerging virus control strategies. Chair: Olaf Horstick (WHO, Switzerland) 8:30-9:15 am Eva Harris (UC-Berkley, USA) « Dengue: From the bench to the field and back » 9:15-10:00 am Xavier de Lamballerie (Universite Aix Marseille 2, France) « Arbovirus evolution and quasispecies: arguments for implementing antiviral treatments » 10:00-10:30 am COFFEE BREAK 10:30-11:00 am Jerome Deval (Roche, Palo Alto, USA) « Inhibiting the polymerase of Dengue Virus: a Company perspective » 11:00-11:30 am Julien Lescar (Nanyang Technological University, Singapore) « Structural views of the NS3 and NS5 proteins from flaviviruses » 11:30-12:00 pm Robert S. Fuller (USA) « A novel family of pharmacologically-validated, non-competitive inhibitors of furin as potential broad spectrum anti-virals and anti-microbials » 12:00-12:30 pm Panelists: Bruno Canard (CNRS, France) Cecilia Dayaraj (NIV, India) Subhash Vasudevan (Duke-NUS Graduate Medical School, USA) Paul Young (University of Queensland, Australia) Wendy Hill (ICAV, Canada) 12:30-1:00 pm Discussion 1:00-2:00 pm LUNCH Formal Poster Presentation Session 2:00-5:00 pm Poster Session 2:30-3:30 pm MOU Signing (by invitation only) 3:30-4:30 pm International Steering Committee Meeting (by invitation only) 7:00-9:00 pm COCKTAILS AND DINNER - 10 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France Focus: Emerging viruses impose a large number of totally novel constraints on society. Not only is scientific knowledge lacking regarding rapid implementation of control measures (eg. antivirals, vaccines), but challenges associated with vector control, community reaction and education, as well as funding schemes to develop efficient protective measures are totally undeveloped. The current preparedness and response plans developed by public health agencies have not involved or engaged classical stakeholders, such as companies and academics, in a landscape where most response schemes (eg. classical grant-funded research, massive and rapid diagnostics, clinical trials, patient care…) are not suitable to face a crisis situation and need significant input from these sectors. This session will work on the identification and bridging of the numerous gaps in this rapidly evolving field. The rapid emergence and spread of H1N1 with gene segments from swine, avian and human origin demonstrates the need for continued surveillance of all known reservoirs for influenza and the refinement of predictive methods for human-to-human transmission and virulence. Session 4 will focus on the global public health responses to the H1N1 pandemic and how they could be improved. A non-academic view Chair: Nabil Seidah (IRCM, Canada) 8:30-9:15 am Ernest Gould (Oxford University, Oxford) « Emerging Viruses: Humans are man’s worst enemy! » 9:15-10:00 am Pilar Najarro (Arrow, UK ) « Industry’s challenges in antiviral drug discovery: a not-so-small company point of view » 10:00-10:30 am COFFEE BREAK 10:30-11:00 am Noël Tordo (Institut Pasteur, France) « Antiviral strategies against negative strand RNA viruses » 11:00-11:30 am Panelists: Rolf Hilgenfeld (University of Lübeck, Germany) Guenter Kraus (Tibotec, Belgium) Brahm Srivastava (CDRI, India) 11:30-12:00 pm Discussion 12:00-1:30 pm LUNCH ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 11 - Focus on significant candidates Chair: Ernest Gould (University of Oxford, UK) 1:30-2:15 pm Angela McLean (Oxford, UK) 2:15-3:00 pm Guy Boivin (Québec City University Hospital Center, Canada) 3:00-3:30 pm COFFEE BREAK 3:30-4:00 pm Bruno Canard (Laboratoire AFMB, France) « Modeling Pandemics » « Influenza resistance to neuraminidase inhibitors” 4:00-4:30 pm « Broad spectrum preparedness against emerging viruses: Achievements of the VIZIER project. What’s next? » Ernest Gould (University of Oxford, UK) « EVA - European Virus Archive » 4:30-5:00 pm Panelists: Johan Neyts (University of Leuven, Belgium) Dale Cumming (ICAV, Canada) Junli Liu (China CDC/IST, China) Dana Wolf (Hadassah University Hospital, Israel) Yossef Av-Gay (University of British Columbia, Canada) Eleanor Fish (UHN, Canada) 5:00-6:00 pm Discussion 7:00-9:00 pm COCKTAILS AND GALA DINNER - Pierre Jeanniot (FAV, Canada) 9:00 pm Closing Comments - Michel Chrétien (OHRI, Canada) Tuesday, October 6 Sessions 6: Late Breaking News Chair: TBA 9:00 am-12:00 pm Rolf Hilgenfeld Eleanor Fish - 12 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 13 - SPEAKER BIOGRAPHIES Bruno Canard Yossef Av-Gay Professor at the Division of Infectious Diseases Department of Medicine at the University of British Columbia, Vancouver, Canada. He is a microbiologist engaged in preclinical studies of respiratory pathogens leading to antimicrobial and antiviral drug development. His research focuses on basic scientific understanding of Mycobacterium tuberculosis and Influenza physiology within the human host. His and Dr. Chris Miller’s application for the use of gaseous nitric oxide as a broad range drug for pandemics was recently approved by Health Canada for safety studies in human volunteers. Prof. Av-Gay has authored more then 50 peer-reviewed scientific publications, review articles, book chapters and holds 10 patents. He serves on scientific advisory boards and is a consultant to several biotechnology companies. Prof. Av-Gay is also a member of the scientific review panels of the Canadian Institute of Health Research and the European Commission. Anne-Sophie Beignon She obtained her PhD degree at the University of Strasbourg in 2002 after spending three years in the laboratory of Dr S. Muller working with Dr C.D. Partidos on skin immunization. Skin had been described as an impermeable barrier for the penetration of large molecules and, back in 1999, it was re-emerging as a potent route for non-invasive delivery of vaccines. Dr. Beignon then joined the laboratory of Dr N. Bhardwaj in NYC in 2002 as a postdoctoral fellow where she characterized the immunostimulatory capacities of R-848, a cheap synthetic molecule designed in the early eighties and back on stage because of the identification of its receptor, i.e. TLR7 and 8, and its potential use as transcutaneous adjuvant. She has also worked on the biology of plasmacytoid dendritic cells, which express TLR7 and 9 and found that HIV activates them via TLR-viral RNA interactions. Dr. Beignon now continues her research at the Institut Pasteur with Dr P. Charneau using lentiviral vectors derived from HIV as vaccine vector against HIV infection itself. Guy Boivin He’s a medical microbiologist/virologist and an infectious disease specialist working at the Québec City University Hospital Center (CHUQ-CHUL) in Canada. Dr. Boivin is also a professor of medical biology (division of microbiology) at Laval - 14 - University and a senior researcher in virology at the Research Center in Infectious Diseases of the same University. Dr. Boivin holds a MD from Laval University, an MSc degree in microbiology from University of Montréal and 3-year specialized research training (Fellowship) in Molecular Virology from University of Minnesota. Dr. Boivin is currently the holder of the Canada research chair on Emerging Viruses and Antiviral Resistance (2006-13). He is also the director of the Canadian Center of Excellence on Herpesviruses and he holds numerous research grants from governmental health organizations (Canadian Institutes of Health Research, Quebec Health Research Foundation) and private companies. His main research interests concern the diagnosis, pathogenesis and treatment of viral diseases caused by herpesviruses (mainly cytomegalovirus and herpes simplex virus) and respiratory viruses (mainly influenza virus, human metapneumovirus and human respiratory syncytial virus) and the mechanisms of resistance to antiviral drugs. Dr. Boivin is a member of several distinguished societies including the American Society for Microbiology, the American Society of Transplantation, the Canadian Association of Medical Microbiology and Infectious Diseases, the Canadian Society for Clinical Investigation and the Quebec AIDS and Respiratory Diseases Networks. In addition, Dr. Boivin has published more than 150 peer-reviewed manuscripts and presented more than 200 communication abstracts since 1993. He is on the Editorial board of the Journal of Infectious Diseases, Herpes Journal and the Canadian Journal of Infectious Diseases. James Brandful Molecular virologist and Head of the Department of Virology of Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana, one of Ghana’s most prestigious biomedical research institutes. His work since the late 80s has focused mainly on enteroviruses, namely Coxsackie A24 variant and EV70 responsible for a highly infectious but limiting haemorrhagic eye condition which broke out extensively in Ghana in the 70s and 80s. He has also worked extensively on the molecular epidemiology and phenotypic characterization of HIV in Ghana and implications for antiretroviral therapy, HPV and cervical cancer in Ghanaian women and some serum biomarkers associated with HIV/AIDS progression. He has an interest in viral haemorrhagic and emerging diseases and the development of antivirals against such conditions. ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France Xavier de Lamballerie Director of Research in the French research agency CNRS, and is the AFMB deputy director. He got his PhD in the Pasteur Institute under the supevision of Dr S.T. Cole in 1991. He was recruited to a permanent position in the CNRS in 1992. He took a post-doctoral position at Harvard Medical School from 1995 to 1998 in the laboratory of Pr. Charles C. Richardson, where he started his research on HIV RT-mediated drug resistance, which later led to his focus on viral replicases. He got an ATIPE starting grant in Marseille in 1998 in the AFMB laboratory headed at that time by Dr. Christian Cambillau. In 2004, both Christan Cambillau and Bruno Canrd launched the VIZIER project, a structural genomics project addressing RNA virus replicases. Bruno Canard took the coordination of VIZIER in July 2005. VIZIER contributed to 85 structures of viral enzymes (AFMB was involved in more than 45 of them). VIZIER exemplifies how shared resources and a strong project culture can boost research in virology and antiviral research. The project has been elected as an EU-FP6 success story. Dr. Canard is presently in charge of the AFMB group «Viral replication: structure, mechanism, and drugdesign» in the AFMB Structural Virology department. The Structural Virology department counts 25 to 30 people, and has set up an open platform for protein production, protein 3D determination and replicase assays. The AFMB has also hosted EMBO practical courses in 2005 and training activities relevant to ongoing projects. Bruno Canard has published 115 articles in refereed journals and has deposited >26 structures in the PDB (September 2009). He has been awarded the William Prusoff prize for antiviral research in 2008. Jeremy P. Carver Co-founder and CEO of ICAV. He is also Chair of the Advisory Committee of the NRC Institute for Biological Sciences and is a Director of Translational Medicines, a Boston biotechnology company. Dr. Carver is an Emeritus Professor of the University of Toronto and an Honorary Conjunct Professor at Trent University. Dr. Carver chaired the Board of the Protein Engineering Network of Centres of Excellence (PENCE) from 2002 until 2006. From 1994 to 2002 he was the Founding President, CEO and CSO of GlycoDesign Inc. He was a Professor and Associate Dean in the Faculty of Medicine at the University of Toronto (1968 - 1994), a Helen Hay Whitney Postdoctoral Fellow at Oxford University (1966-68) and a World Trade Visiting Scientist at IBM Watson Labs, New York (1977). He has a degree in Chemistry and a Doctorate in Medicine from the Univesity of Marseilles, where in 1995 he also obtained his PhD. He is currently Professor of Microbiology at Marseille Medical University’s Emerging Viruses Unit, where he is responsible for overseeing the Virology Department research programme. Dr. de Lamballerie is also in charge of the Virology Unit of the Microbiology Department at La Timone Hospital, Marseille. In 1996 Dr. de Lamballerie was the first to demonstrate the nosocomial transmission of the Hepatitis C virus in haemodialysis units using phylogenetic tools. During the same year he established the first research laboratory dealing with clinical virology in collaboration with Professor Ph. De Micco. This unit is specialised in diagnosis, genomics and genetics of RNA viruses and established the complete sequences of more than 40 RNA viruses including flaviviruses, arenaviruses and reoviruses. In 1997 he was the first to conduct epidemiological and molecular studies in Europe on the GB virus-C and on the TT virus, and in 1998 he established the first genomic sequences and taxonomic classification of Coltiviruses and a new genus - the Seadornavirus genus - within the Reoviridae family. Regarding avian/human influenza, Dr. de Lamballerie is the coordinator of Section 2 (Virus Production and Genome Sequencing) of the EU-funded VIZIER programme. This programme aims to have a groundbreaking impact on the identification of potential new drug targets against RNA viruses by providing a comprehensive structural characterization of the replicative machinery of a carefully selected and diverse set of viruses. Dr. de Lamballerie is thrilled to be part of VIZIER, which he describes as unique because it gathers experts from a vast range of scientific disciplines and gets them working together in a major structural effort, within a broad multidisciplinary study that has virology upstream and target validation downstream. To date, more than 350 species of viruses that possess an RNA genome and can infect vertebrates have been identified, but only 30% have been sequenced. VIZIER has developed a strategy for the rapid characterization of the missing genomes; work which Dr. de Lamballerie endorses with great enthusiasm. Moreover, he is particularly appreciative of the efforts that the EU has taken to get this complex project up and running. He is confident that it will have an extremely beneficial effect on society. VIZIER: Comparative structural genomics on viral enzymes involved in replication ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 15 - Jerome Deval Graduated in 2000 from the engineering school of ESIL in France, with a major in Biotechnology. Immediately after, Jerome started a PhD program in Biochemistry under the supervision of Dr. Canard at the French CNRS in Marseille. During that time, Jerome studied mechanisms of resistance of HIV reverse transcriptase to nucleoside analogues. After he graduated with his PhD in 2004, Jerome joined the laboratory of Dr. Gotte at McGill University in Canada, where he established methods to study the inhibition of the polymerase of hepatitis C virus in vitro. Jerome is now a research scientist in the Virology department of Roche in California. He is the lead biochemist for the dengue virus project, and also supports other programs such as HCV. Jerome is married and has two children. Eleanor Fish She’s the Canada research chair in Women’s Health & Immunobiology, a McLaughlin Scholar and was elected as a Fellow to the American Academy of Microbiologists. Dr. Fish received her undergraduate degree at the University of Manchester, England, and her Master of Philosophy in Virology at the University of London, England. She completed her PhD in Cell Biology at the Institute of Medical Science at the University of Toronto, Canada. Dr. Fish is a member of several societies, including the American Society for Biochemistry and Molecular Biology, the Canadian Society for Immunology, the International Cytokine Society, and the International Society for Interferon and Cytokine Research, for which she is President. She is on the editorial board for the Journal of Interferon and Cytokine Research. Her work has been published in many scientific journals, such as the Journal of Immunology, Experimental Hematology, Circulation, Blood, Nature, PNAS, JAMA and the Journal of Biological Chemistry. Dr. Fish studies the interactions of cytokines, specifically interferons and chemokines, with their receptors in normal and diseased tissues and cells. A focus of Dr. Fish’s research is associated with autoimmune diseases, specifically rheumatoid arthritis, multiple sclerosis and lupus. Dr. Fish’s research involves biomarker discovery to develop intervention therapeutics for patients with RA. Another major focus of her work is the investigation of host-pathogen interactions at the cellular and molecular level, specifically in the context of interferons and chemokine receptors. During the 2003 outbreak of SARS in Toronto, she initiated studies to investigate the therapeutic potential of interferon in SARS patients. Encouraging results have directed her group’s efforts toward examining interferon activity against a number of emerging infectious diseases, such as avian flu. - 16 - Robert S. Fuller Professor of Biological Chemistry at the University of Michigan Medical School. Dr. Fuller obtained his BS (1978), in Molecular Biophysics and Biochemistry at Yale University and his PhD (1984) in Biochemistry, from Stanford University. He completed Postdoctoral training from 1984-1987 in Microbiology and Immunology & Biochemistry at the University of California, Berkeley. From 1987-1994 Dr. Fuller was Assistant Professor, Biochemistry, at Stanford University. From 1994-1999 he was an Associate Professor, Biological Chemistry at the University of Michigan; and from 1999-present he is a Professor, Biological Chemistry at the University of Michigan. Dr. Foster has received many awards: 1978, magna cum laude, Yale University; 1978-1984, NIH predoctoral trainee; 1984-1987, Helen Hay Whitney Postdoctoral Fellow; 1986-1992, Lucille P. Markey Scholar; 1990 SmithKline Becham Scholar Award; 2000, Faculty Recognition Award, University of Michigan. His research has included: PhD research with Professor Arthur Kornberg: replication of the bacterial chromosome and role of DnaA protein; Postdoctoral, with Professor Jeremy Thorner: Processing by proprotein processing protease, Kex2, in yeast; Independent: Proteolytic processing in the secretory pathway; biochemistry, structure and function and inhibition of proprotein processing proteases; protein localization and processing in the secretory pathway; yeast cell biology. Ernest Gould He started his virology career as a Postdoctoral fellow at the University of Birmingham and was then appointed lecturer at Queen’s University Belfast, subsequently becoming a senior lecturer in the London School of Hygiene and Tropical Medicine. He was then appointed Assistant Director at the Institute of Virology in Oxford where he focused his research on Arboviruses. During the past 25 years he has developed a strong interest in viral pathogenesis, evolution, persistence, and emergence, and has published nearly 200 papers on these subjects. In 2003, he retired from his position as Director in Oxford and is now working as a Visiting Professor in the Unité des Virus Emergents, Marseille, where Professor Xavier de Lamballerie is the Head. ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France Eva Harris Rolf Hilgenfeld She’s currently a Professor in the Division of Infectious Diseases in the School of Public Health and Director of the Center for Global Public Health at the University of California (UC) Berkeley. She received a BA in Biochemical Sciences from Harvard University and a PhD in Molecular and Cell Biology at UC Berkeley. As a faculty at UC Berkeley, she has developed a multidisciplinary approach to study the molecular virology, pathogenesis, and epidemiology of dengue, the most prevalent mosquito-borne viral disease in humans. One major research focus has been the development of a mouse model to study viral tropism and pathogenesis, investigate the immune response to dengue virus infection, and generate a better model of disease. This has resulted in a mouse model for antibody-dependent enhancement of dengue disease that is being used extensively to test different classes of candidate antiviral compounds that target 1) the virus itself, 2) host processes essential for dengue virus infection, 3) the interaction between virus-immune complexes and the Fc receptor, and 4) vascular leak syndrome. Another area of research is the mechanism of viral translation and replication, particularly cis-acting elements in the viral genome. Her field work focuses on laboratory-based and epidemiological studies of dengue in endemic Latin American countries, particularly in Nicaragua, where ongoing projects include clinical and biological studies of severe dengue, a pediatric cohort study of dengue and influenza transmission in Managua, and a project on evidence-based, community-derived interventions for prevention of dengue via control of its mosquito vector. She has also collaborated with investigators in the Department of Electrical Engineering at UC Berkeley to develop novel, rapid, low-cost diagnostic devices for point-of-care diagnosis of dengue and other infectious diseases. In 1997, Dr. Harris received a MacArthur “Genius” Award for her pioneering work over the previous ten years developing programs and working to build scientific capacity in developing countries to address public health and infectious disease issues. To continue and expand this work, in 1998 she founded a non-profit organization in San Francisco, Sustainable Sciences Institute (SSI; www.ssilink.org) and published a book on the subject with Oxford University Press. She was co-Director of the Fogarty International Center’s «International Training and Research in Emerging Infectious Diseases» program at UC Berkeley from 1997-2003. In 2001, Dr. Harris was named a Pew Scholar for her work on dengue pathogenesis. In 2002, she received the Prytanean Faculty Award for outstanding women faculty as well as a national recognition award from the Minister of Health of Nicaragua for her contribution to scientific development, and she was selected as a “Global Leader for Tomorrow” by the World Economic Forum. Dr. Harris has published over 90 peer-reviewed articles, as well as a book on her international scientific work. He was among the first scientists to determine the structure of the HIV-1 protease and to design inhibitors against this target. Since 2003, Dr. Hilgenfeld has been Full Professor of Biochemistry at the University of Lübeck, Germany. His research focuses on the molecular basis of infectious diseases by bacteria such as Legionella pneumophila and Chlamydia and by RNA viruses. During the global SARS epidemic of 2003, he published the crystal structure of the coronavirus main proteinase and proposed a first inhibitor against the disease. His Lübeck laboratory follows an integrated approach to drug discovery against infectious agents, which includes comparative proteomics, molecular biology, X-ray crystallography, drug design and chemical synthesis of inhibitors. Jörg Hofmann He completed his PhD in organic chemistry at the Karl-Marx-University Leipzig. From 1988 – 1995 he held a Postdoctoral position at the Institute of Medical Microbiology, Department of Virology, at the University of Leipzig. From 1995- 2006, Dr. Hofmann was a Postdoctoral research fellow at the Institute of Virology at the University of Leipzig. Since 2006 Dr. Hofmann has been head of the diagnostic department of the Institute of Medical Virology, Charité University Hospital Berlin. Evelyne Jacqz-Aigrain Medical doctor who graduated from the University René Descartes in Paris, France. She trained in Paediatrics at the Hospital Necker-Enfants Malades during a four year residency and was associate Professor in Paediatrics and Neonatal Intensive care for two years. She trained as a post doctoral research fellow in Clinical Pharmacology with Pr C. Dollery in London UK, and with J. Oates and G. Wilkinson in Nashville, USA, and graduated with a PhD in Pharmacology. She worked for four years as a researcher at INSERM. She is now head of the Department of Paediatric Pharmacology and Pharmacogenetics, hospital Robert Debre, in Paris, France and responsible for the “French Network of Paediatric Clinical investigation Centers. She is also an active member of the European Society for Developmental, Perinatal and Paediatric Pharmacology. ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 17 - Pierre Jean Jeanniot Chairman of the Foundation on Antivirals and Director General Emeritus of the International Air Transport Association, a lifetime title awarded in recognition of his outstanding contribution IATA and to international civil aviation. He currently acts as advisor to the worldwide THALES Group, SECOR Consulting and Jet Airways (India), and Chairs the Boards of a number of IT companies. Pierre Jeanniot was President and CEO of Air Canada from 1984-1990 and early in his aviation career he was instrumental in developing the famous “Black Box”. He has devoted himself to many social and charitable causes, and was Chancellor of the Université du Québec à Montréal - UQÀM until 2008, having previously been Chairman of the Board, and President of its Foundation. He was also Honorary President of the Canadian Cancer Society’s fund-raising campaign. Mr. Jeanniot is an Officer of the Order of Canada, a Chevalier de la Légion d’Honneur in France, and received the Independence Medal of the First Order from H.K. King Hussein of Jordan in 1995. Mr. Jeanniot holds a Doctorat Honoris Causa, from the Université du Québec, an Honorary Doctorate in International Law from Concordia University, and an Honorary Doctorate in Science from McGill University. He is a Fellow of the Royal Aeronautical Institute and has been indicted into the Québec Hall of Fame. Guenter Kraus Tibotec’s Infectious Disease and RED Liaison Officer. He is leading the early development efforts at Tibotec and responsible for scientific liaison of Research and ED programs and novel infectious diseases initiatives. Before taking on this role he was Sr. Director in the clinical virology department leading the clinical virology laboratory. Dr. Kraus’s academic credentials span more than 12 years of antiviral research at UCSD and the University of Miami. Guenter received his training in virology at the Paul-Ehrlich-Institute. Julien Lescar Associate Professor with the School of Biological Sciences, Nanyang Technological University (NTU), Singapore. He directs research programs on the structural biology of neglected infectious diseases caused by RNA viruses and malaria. He has made contributions to the structural virology of positive strand RNA-viruses which comprise several important human pathogens. Having determined the first 3D structures for flavivirus and alphavirus envelope proteins, and several key viral enzymes including the helicase, protease and polymerase from dengue virus, he is one of the leading Dengue structural biologists worldwide. During the last five years, he has been - 18 - collaborating with the Novartis Institute for Tropical Diseases in Singapore and also with the group of Bruno Canard, CNRS Marseille. He set-up the X-ray crystallographic facility at NTU, which currently comprises one Rigaku micromax007HF generator and two imaging plate detectors a facility which is running 24/7 and is also used by local biotech companies. He is a regular reviewer for MRC grants (UK), European grants and for international journals like J. Virol., Virology, Structure, Plos-Pathogens, Molecular Microbiology, RNA, Virus Research, Antiviral Research, Biochemical Journal, Biochemistry, Proteins, Protein Science, Febs Journal among others. He has published more than 50 peer reviewed articles that have attracted more than 1000 citations and is the author of one provisional US-patent on a monoclonal antibody that inhibits all four dengue serotypes. Angela McLean She studied mathematics at Oxford followed by a PhD in biomathematics at Imperial College, London. After a brief spell in the City she joined the Mathematical Biology Group at the National Institute for Medical Research at Mill Hill. Dr. McLean returned to Oxford as a Royal Society University Research Fellow in 1990 and took a secondment to the Institut Pasteur in Paris in 1994. In 1998 she became Head of Mathematical Biology at the BBSRC’s Institute for Animal Health. Returning to Oxford in 2000, Dr. McLean became Professor of Mathematical Biology in 2004. In 2005 she became Director of the Institute for Emerging Infections – a founding Institute of the James Martin 21st Century School. Since 1st October 2008 she has been a Senior Research Fellow at All Souls College. Pilar Najarro Head of Virology at Arrow Therapeutics (a wholly owned subsidiary of Astra Zeneca) and has contributed to the development and successful application of methodology to elucidate the mode of action and genetic barrier of resistance of small molecule antivirals. Several of those are now in clinical development. Prior to joining the pharmaceutical industry four years ago Dr. Najarro’s efforts were mainly focused on host-pathogen interactions and viral immune evasion. After completing BSc and MS studies at the Universidad Autónoma in Madrid, Dr. Najarro received her PhD in vaccinia-cell interactions at the State University of New York Downstate Medical Centre in Brooklyn, followed by a post-doctoral fellowship at the Wright-Fleming Institute at the Imperial College in London. ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France Oyekanmi Nash Director of the African Regional Office of the International Consortium on AntiVirals (ICAV), is the Deputy-Director (Collaboration and Linkages) with the National Biotechnology Development Agency (NABDA), Federal Ministry of Science and Technology, Abuja-Nigeria. He is also the Coordinator of the Initiative for Translational Research on Tropical and Emerging Infectious Diseases at the NABDASouthwest Biotechnology Centre of Excellence at the University of Ibadan. He is an Adjunct Lecturer with the Institute for Advanced Medical Research and Training, College of Medicine, University of Ibadan. Before returning to Nigeria in 2006, he was a Research Associate with the Department of Microbiology and Immunology, Albert Einstein College of Medicine, New York, where he worked on the evolution of HIV-1 Reverse Transcriptase for Molecular Biology applications. As a Post-Doctoral Fellow with the Canadian Protein Engineering Centre of Excellence (PENCE), he had worked on the engineering of the first «Mannosynthase.» at the University of British Columbia, Vancouver, Canada. He is the Program Director of the West African Biotechnology/Bioinformatics Workshops Series (WABWS). Johan Neyts Full professor of virology at the University of Leuven. His research is focused on the development of novel antiviral strategies against a number of RNA viruses including picornaviruses, flaviviruses and HCV. He has also a long standing expertise with respect to the development of small animal models for flavivirus infections and with the molecular virology of flaviviruses. His team discovered the anti-HCV activity of Debio-025, a compound which is now in phase II clinical development by DebioPharm (Lausanne, Switzerland). Together with Prof. Gerhard Puerstinger (University of Innsbruck, Austria) he also discovered a novel class of HCV inhibitors, of which the potent compound GS 9190 is now in phase II clinical development at Gilead Sciences (Foster City, CA, USA) and together with Prof. C. Mc Guigan (University of Cardiff) he discovered a novel prodrug approach to treat HCV infections (in preclinical development at Inhibitex, Alpharetta, Georgia). He is inventor on a number of patents in the antiviral field of which the majority have been licensed to commercial third parties and his work has been published in several book chapters and in about 200 papers in international scientific journals of high impact (~ 3500 citations). He is on the editorial board of the journals ‘Antiviral Research’ and ‘Antiviral Chemistry and Chemotherapy’, ad hoc reviewer for about 30 scientific journals, member of several national and international scientific committees and on the Board of Directors of the International Society for Antiviral Research. He is the CSO and co-founder of the KULeuven spin-out company Okapi Sciences NV. He has given close to 100 invited lectures. He is teaching medical virology at the school of dentistry and the school of medicine at the KULeuven. He has been honored with a number of awards including the Dr. Schamelhout-Koettlitz prize from the Royal Belgian Academy of Medicine, the Princess Josephine Charlotte prize from the Belgian Fund for Scientific Research and the William Prusoff Lecture Award from the International Society for Antiviral Research. The Neyts lab has been partners in four EU FP6 funded consortia, i.e. a “Network of Excellence”, VIRGIL [www.virgil-net.org] on antiviral drug resistance, the “Integrated Project” VIZIER [www. viziereurope.org] on the replication machinery of RNA viruses as targets to inhibit viral replication, a “specific targeted project” “Dengframe” [www.denframe.org] to identify strategies to control dengue and the “Coordinated Action” RiviGene [www15.bni-hamburg.de/ bni/others/rivigene] on highly pathogenic viruses. He is the coordinator of a large NIAID/NIH funded project on poxvirus inhibitors and of a major project, funded by the Wellcome Trust, on Dengue drug discovery. Sunday Omilabu He’s head of the Virology Research Unit, Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos, Nigeria. He is the current Dean, School of Basic Medical Sciences, CMUL. His academic and professional Qualification. Include a BSc (Hons) Ife, MSc, and a PhD (Ibadan). Dr. Omilabu’s main research topics include: Identification and characterization of viruses circulating in Nigeria; epidemiology of some viruses of medical/zoonotic importance in Nigeria; potency and efficacy of live viral vaccines used in Nigeria; antiviral activities of tropical medicinal plants; and molecular diagnosis of viruses of public health importance in Nigeria. In collaboration with a group in Luxembourg, wild Measles virus strains circulating in Lagos were characterized using molecular biology techniques. Together with a group in Stuttgart, Germany, rotavirus isolated from diarrhoeic children in Lagos was identified and genetically characterized. The first Nigerian strain of rotavirus was successfully adapted to tissue culture and activity of Rotavirus, Adenovirus, and Astrovirus in diarrhoeic children in Ilorin, Nigeria, was investigated. Currently, S.A. Omilabu’s laboratory collaborates with a group in Germany on the molecular typing of Lassa fever virus circulating in Nigeria. In a series of collaborative studies with the departments of Paediatrics and Surgery of the College of Medicine, University of Lagos, viruses causing acute respiratory tract infection in children in Lagos were isolated and identified for the first time. S.A. Omilabu’s contributions on viral epidemiology in Nigeria include distribution and ecology of important viruses causing human diseases in Nigeria, including Potiskum virus, Igbo-Ora virus, Influenza virus, Yellow fever virus, West Nile virus, Wesselsbron virus, Cytomegalovirus, African Horse Sickness virus, Human Immunodeficiency virus and Lassa fever virus. ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 19 - Ramesh S. Paranjape Ramesh S. Paranjape is the Director of the National AIDS Research Institute at the Indian Council of Medical Research, Pune. He has a BSc in Zoology from Fergusson College (1972), an MSc in Medical Microbiology from All India Institute of Medical (1975) and a PhD in Medical Microbiology (1982). Dr. Paranjape joined the services of the Indian Council of Medical Research in 1976 at Chennai. From 1976 to 1993 his area of work included the immunology of Filariasis and Tuberculosis trying to develop diagnostic assays and to understand the responses of human body to these disease causing organisms and the impact of the responses on the disease manifestation. In 1993, Dr. Paranjape joined the National AIDS Research Institute, Pune and the focus of his research was shifted to HIV and AIDS, primarily focused on understanding the immune response to HIV. He currently heads the National AIDS Research Institute, a permanent research institute of Indian Council of Medical Research. The Institute is carrying out programmes for development of HIV vaccine indigenously. A first ever HIV vaccine trial was launched under the leadership of Dr. Paranjape at Pune. As a part of his research career Dr. Paranjape has visited a number of countries, has received training in advanced technologies in prestigious Institutes such as National Institutes of Health, USA and Johns Hopkins University, Baltimore, USA. He has over 100 research publications in national and international scientific journals. He has written popular science articles including a book in HIV and AIDS in Marathi. He is also recognized as guide for PhD studies by Madras and Pune University. Bruno Spire Social researcher in Marseille, France. Born in 1960, he got his MD degree in 1985. He obtained his PhD in virology in 1990. In the early 1980’s he worked in the laboratory at the Institut Pasteur with Françoise Barré-Sinoussi and participated in the first studies aimed at characterizing HIV. In the 1990’s he worked in HIV molecular virology on the role of the /vif/ accessory gene. In 1999, he switched to social sciences and public health issues and focused his work on adherence to antiretroviral treatment, quality of life and risky behaviours of people living with HIV/ AIDS. He has a permanent position in the French National Research Institute for Medical Research and leads his own group in the field of public health applied to HIV. Dr. Spire is openly HIV-positive and is the President of the French community-based NGO AIDES. - 20 - Brahm S. Srivastava Emeritus Scientist at Central Drug Research Institute, Lucknow. He has served as Deputy Director and Head of Microbiology at Central Drug Research Institute and Professor and Chairman of Biotechnology at Jawaharlal Nehru University, New Delhi. Dr Srivastava graduated from Banaras Hindu University with a PhD degree and did Post-doctoral research in Belgium and the USA. He works on virulence factors, pathogenesis, vaccine and diagnosis of Vibrio cholerae and Mycobacterium tuberculosis. He has been elected a Fellow of The National Academy of Sciences, India and American Academy of Microbiology. He has received prestigious awards from CSIR, ICMR, and INSA. Jonathan Stoye Head of the Division of Virology at the Medical Research Council’s National Institute for Medical Research in Mill Hill, London. He received his BA degree from the University of Cambridge, UK; his PhD from Basel University, Switzerland; and postdoctoral training in the laboratory of John Coffin at Tufts University School of Medicine in Boston, Massachusetts, USA. His scientific career has been devoted to understanding the mutual relationship between retroviruses and their hosts with particular emphasis on endogenous retroviruses and host factors such as Fv1 and TRIM5 that limit retrovirus replication. Jan ter Meulen Executive Director of Vaccine Basic Research at the Merck Research Laboratories, West Point, PA. He is responsible for the leadership of the department, overseeing all laboratory research on vaccines in the field of infectious diseases, ranging from the identification of protective antigens to testing vaccine candidates in non-human primates. He holds an adjunct professorship of virology at the University of Marburg, Germany, is a board certified medical microbiologist, holds a diploma in tropical medicine (London), and is a member of the College of Physicians of Philadelphia. Prior to joining Merck & Co. in 2008, he worked for five years at Crucell Holland bv on the discovery and development of novel vaccines and human monoclonal antibodies against multiple infectious diseases targets, e.g. Ebola, SARS, West Nile, H5N1 influenza, grampositive bacteria and P. falciparum. Dr. ter Meulen pursued his academic career with a focus on tropical viruses at the German Center for Cancer Research, Heidelberg, the Bernhard Nocht Institute for Tropical Medicine, Hamburg, and the Philipps University, Marburg. From 2000-2005 he was an International Scholar of the Howard Hughes Medical Institute in the Infectious Diseases and Parasitology program, through which ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France he received support for his field studies on Lassa fever in West Africa. He has over 60 peer-reviewed publications, is an associate editor of the Journal of Clinical Virology, and served as a consultant and reviewer to the German Ministry of Science and Education, the Scientific Directorate of the European Community, the International Science and Technology Center, Moscow (ISTC), and the NIH. Noel Tordo Directeur de la Recherche Technologique au CEA, Directeur du CEA Grenoble. His role is “Chef de Laboratoire” at the Pasteur Institute, Department of Virology. Dr. Tordo graduated from the DEA - Molecular and Cellular Biology (1981), Strasbourg and completed his PhD in MicrobiologyVirology in 1988, Paris VII HDR (1993). Dr. Tordo is the Director of the Course of Fundamental Virology, Pasteur Institute; Organisation of Theoretical & Practical Virology Courses in France, in Europe (Portugal, Bulgaria, Finland, Sweden) and elsewhere (Brasil, Hong-Kong, Algeria, Morocco); Organisation of Congress, Seminars, Workshops (France, Belgium, Turkey, Portugal, Algeria, South-Africa, Brasil, Mexico, USA); Redaction, Editorial Board, Societies :J. Gen. Virol., Microbes & Infection, Annales IP, Iranian Med. J., Virologie Member of the French Society for Microbiologie, AAEIP, European Society for Vet. Virol., Basilian Society for Virology; and the Director of the Course of Fundamental Virology, Pasteur Institute. His other responsibilities include: -ICTV: Head of the Rhabdovirus Study Group -WHO-PAHO-private companies: Expert, Consultant -INRA: Scientific Council Animal Health (member) -AFSSA: Scientific Council Animal Health (member) -International Consortium for Antivirals (co-founder) -Scientific commitees (Pole génomique de Shanghai) -Expert for Scientific Journals (reviewer), -Scientific Insitutes (INRA, IRD, CNEVA, CIRAD) -Director of the Course of Fundamental Virology, Pasteur Institute Dr. Tordo has received the Académie Nationale de Médecine (1987); the Académie des Sciences (1988) and the Chevalier des Palmes Académiques (2006) Queensland which presented attractive and relevant research opportunities. Dr. Vasudevan rose through the ranks (Senior Lecture (1997), Reader (2000)) and in January 2003 made a career detour to become the Head on Dengue Research at the newly established Novartis Institute for Tropical Diseases (NITD) that has as its core, the mission to discover anti-Dengue drugs for therapeutic and possibly preventative use. He played a significant role in advancing this course by building a world-class dengue research department and developing a strong pipeline of projects. Dr. Vasudevan was also one of the key drivers in establishing NEHCRI, a collaboration between two major Indonesian Institutions and NITD with laboratories in Makassar and Jakarta. In March 2008 he joined the Duke-NUS Graduate Medical School where he is an Associate Professor and Principal Investigator in the Program in Emerging Infectious Diseases. Anna Vyakarnam She gained a 1st Class BSc Hons in Microbiology from the University of Poona, India, after which she studied for an MSc in Applied Immunology at Brunel University. She then studied for her PhD at Cambridge University, after which she worked as a Post doctoral researcher at the University of Cambridge. She then joined University College London, as an Honorary Lecturer.She is currently a Senior Lecturer in Infectious Diseases at King’s College London. One objective of her group is to identify and characterise host cell factors that regulate HIV infection. The strategy is based on the knowledge that human CD4 T-cells of the same genetic origin can differ substantially in their susceptibility to HIV infection, despite expression of the critical HIV receptor / co-receptors. The second objective of Dr.Vyakarnam’s group is translational research in elucidating the antiviral and immune regulatory properties of CD4 T-cells from patients who do exceptionally well clinically following HIV infection (so called long-term non-progressors {LTNP}) or following multiple exposures to HIV (so called highly-exposed persistently seronegative individuals {HEPS}). Subhash Vasudevan He obtained his BSc Hon (1985) from LaTrobe University and his PhD (1989) in Biochemistry from the Australian National University. His first postdoctoral fellowship was completed at the Max Planck Institute for Biophysics (1989-1991) and after spending another year in the at the Research School of Chemistry at the Australian National University he was appointed as a Lecturer in the Biochemistry and Molecular Biology Department at James Cook University (Jan 1993) in Australia. The first year of his position coincided with a dengue outbreak in North ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 21 - Dana Wolf Senior Physician in Infectious Diseases, and the Director of the Clinical Virology Unit and the Clinical Virology Laboratory at the Hadassah University Medical Center, Jerusalem, Israel. Her areas of interest include: The epidemiology and impact of known and newly discovered respiratory viruses as revealed over a prospective 5-year study in young children; Human cytomegalovirus replication mechanisms and novel antiviral drug targets - including the antiviral activities of new UL97 kinase inhibitors, and the anti-malarial artemisinin derivatives; Human cytomegalovirus antiviral drug resistance; Congenital cytomegalovirus infection: determinants of transmission and disease; and the role of viral immune evasion mechanisms. Prof. Wolf is a member of the Israeli Ministry of Health Advisory Committee on Immunization Practices and Infectious Diseases, the National Pandemic Preparedness Team, and the European Congenital CMV Initiative. NOTEPAD Paul Young He completed his Honours degree at QIMR in 1976. He then moved to the UK where he completed his PhD studies on the arenaviruses at the London School of Hygiene & Tropical Medicine. He became a member of academic staff and began his dengue research program in 1986, initially in the area of vaccine development. After 11 years at LSHTM he returned to Australia in 1989 to SASVRC, Royal Children’s Hospital with a UQ joint appointment as Senior Lecturer. He transferred to a full-time appointment at UQ in 2000. His current interests are in the molecular virology, diagnosis and control of dengue and West Nile viruses as well as respiratory syncytial virus. His group is also studying the engagement currently being enacted in the wild between a novel retrovirus and its host, the koala, and what this can tell us about cancer induction and viral evolution. - 22 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 23 - - 24 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 25 - - 26 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France - 27 - - 28 - ICAV 8TH INTERNATIONAL SYMPOSIUM - CHALLENGING PANDEMICS : SCIENCE, FUNDING AND POLICY October 3rd - 6th, 2009 - Corsica, France